IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: “Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials”

August 8, 2024

https://www.prnewswire.com/news-releases/icecure-announces-positive-data-from-the-largest-multi-institutional-study-of-its-kind-cryoablation-of-primary-breast-cancer-in-patients-ineligible-for-clinical-trials-302216520.html

CAESAREA, Israel, Aug. 7, 2024 /PRNewswire/ — IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an independent study titled “Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials: A Multi-institutional Study” in a leading radiology journal, the American Journal of Roentgenology (AJR).

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.